Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Molecular genetics and epigenetics in cancer: science fiction or a certainty in therapeutic management

International Conference on Immuno - Oncology and Cancer Science
July 23- 24, 2018 Amsterdam, Netherlands

Mohsen Ghasemi

Motamed Cancer Institute, Iran

Posters & Accepted Abstracts: Arch Can Res


In recent years, advances in molecular medicine have launched disruptive innovations in cancer diagnostics and therapeutics. The advent of genomics and epigenomics has revolutionized our understanding of cancer as several different biologically and molecularly distinct diseases. Molecular profiling, the classification of tissue or other specimens for diagnostic, prognostic, and predictive purposes based on multiple gene expression, is a technology that holds major promise for optimizing the management of patients with cancer. However, the use of these tests for clinical decision making presents many challenges to overcome. Personalized medicine is defined by therapy decisions tailored to individual patients, aiming to improve therapeutic efficiencies and to minimize side effects. The current clinical practice includes targeted therapies for disease-related alterations and molecular biomarker-based patient stratification. However, recent advances in screening technologies have enabled more comprehensive identification strategies and suggest a plethora of additional valuable biomarkers and druggable molecules for future clinical applications. Beside genetic alterations, in particular, epigenetic biomarkers emerge into the field by presenting stable modifications (e.g. DNA and histone modifications) with predictive potential for drug treatment efficiencies, especially in a cancer context. In this talk, we’ll summarize the current use of genetics and epigentics for treatment efficiencies and evaluate their translational value into clinical use in cancer.